Aminologics Co.Ltd (074430) - Total Assets
Based on the latest financial reports, Aminologics Co.Ltd (074430) holds total assets worth ₩87.63 Billion KRW (≈ $59.39 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Aminologics Co.Ltd (074430) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Aminologics Co.Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Aminologics Co.Ltd's total assets have evolved over time, based on quarterly financial data. See 074430 book value for net asset value and shareholders' equity analysis.
Aminologics Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Aminologics Co.Ltd's total assets of ₩87.63 Billion consist of 93.4% current assets and 6.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 31.4% |
| Accounts Receivable | ₩7.46 Billion | 8.9% |
| Inventory | ₩4.44 Billion | 5.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.00 Billion | 2.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Aminologics Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Aminologics Co.Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aminologics Co.Ltd's current assets represent 93.4% of total assets in 2025, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 31.4% of total assets in 2025, up from 23.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 10.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 8.9% of total assets.
Aminologics Co.Ltd Competitors by Total Assets
Key competitors of Aminologics Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩75.43 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩222.34 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩98.92 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
Aminologics Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 13.05 | 6.59 |
| Quick Ratio | 2.59 | 11.50 | 5.50 |
| Cash Ratio | 0.00 | 5.70 | 1.30 |
| Working Capital | ₩52.30 Billion | ₩46.84 Billion | ₩31.58 Billion |
Aminologics Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Aminologics Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 48.2% |
| Total Assets | ₩84.18 Billion |
| Market Capitalization | $65.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aminologics Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aminologics Co.Ltd's assets grew by 48.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aminologics Co.Ltd (2008–2025)
The table below shows the annual total assets of Aminologics Co.Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩84.18 Billion ≈ $57.05 Million |
+48.23% |
| 2024-12-31 | ₩56.79 Billion ≈ $38.49 Million |
-1.52% |
| 2023-12-31 | ₩57.67 Billion ≈ $39.08 Million |
+3.75% |
| 2022-12-31 | ₩55.58 Billion ≈ $37.67 Million |
-14.81% |
| 2021-12-31 | ₩65.24 Billion ≈ $44.21 Million |
+8.51% |
| 2020-12-31 | ₩60.13 Billion ≈ $40.75 Million |
+4.08% |
| 2019-12-31 | ₩57.77 Billion ≈ $39.15 Million |
+1.61% |
| 2018-12-31 | ₩56.86 Billion ≈ $38.53 Million |
+15.17% |
| 2017-12-31 | ₩49.37 Billion ≈ $33.46 Million |
+0.70% |
| 2016-12-31 | ₩49.03 Billion ≈ $33.22 Million |
-10.91% |
| 2015-12-31 | ₩55.03 Billion ≈ $37.29 Million |
+42.44% |
| 2014-12-31 | ₩38.63 Billion ≈ $26.18 Million |
-19.86% |
| 2013-12-31 | ₩48.20 Billion ≈ $32.67 Million |
-8.53% |
| 2012-12-31 | ₩52.70 Billion ≈ $35.71 Million |
-37.39% |
| 2011-12-31 | ₩84.17 Billion ≈ $57.04 Million |
+43.01% |
| 2010-12-31 | ₩58.86 Billion ≈ $39.89 Million |
-11.11% |
| 2008-12-31 | ₩66.21 Billion ≈ $44.87 Million |
-- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more